<DOC>
	<DOCNO>NCT00425490</DOCNO>
	<brief_summary>The study design investigate effect 18 week treatment Sitagliptin 100 mg/day insulin secretion capacity beta cell . Patients meet study enrollment criterion undergo 2 experiment ( see description ) ; grade hyperglycemic technique meal test , prior randomization 12-wk double-blind study period . The treatment effect shed light magnitude beta cell capacity increase mass function .</brief_summary>
	<brief_title>Effect Januvia Beta Cell Function Patients With Diabetes Mellitus</brief_title>
	<detailed_description>Study design duration : This Israeli three center study . Study drug : Sitagliptin 100 mg . The study double blind , randomize two arm parallel group study . The duration study 18 week ( 8 visit ) patient . This include : screening period 4 week ( Visit 1 visit 2 ) , 2 week single blind , placebo run-in period ( visit 2 visit 4 ) , 12 week placebo control , double blind treatment period ( visit 4 visit 8 ) . Patients T2DM treat AHA , AHA monotherapy low dose oral combination therapy ( low dose define ≤50 % maximum label dose agent ) , may participate meet enrollment criterion . Patients eligible randomized HbA1c ³6.5 % £10 % . Patients meet study enrollment criterion undergo 2 experiment ( see description ) ; grade hyperglycemic technique meal test , prior randomization ( Visit 3 4 ) . These experiment complete 12-hour overnight fast . The 2 experiment repeat conclusion 12-wk double-blind study period ( Visits 7 8 ) . Efficacy measurement : ( 1 ) Glycemic control : FPG , HbA1c , β-cell Function Parameters ( Φs , Φd , Φb , Φ , Φob , T ) , Insulin Secretion Rate ( determine C-peptide deconvolution ) , 1st 2nd phase insulin secretion , Insulin response arginine injection , Insulin sensitivity index , glucose , insulin , C-peptide total incremental area curve .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criterion : Patient T2DM diagnose within past 5 year Patient &gt; 18 &lt; 65 year age Patient pregnant , breast feeding unlikely conceive Patient understands study procedure , agree participate study give write informed consent Patient meet one follow criterion : 1 . Patient currently AHA Visit 1 HbA1c ≥6.5 % ≤10 % . OR 2 . Patient currently AHA monotherapy low dose ( i.e . ≤50 % maximum label dose agent ) oral combination therapy Screening/Visit 1 HbA1c ≥6.5 % ≤9.5 % . At visit 2 , patient HbA1c ≥6.5 % ≤10 % Patient type 1 diabetes mellitus Patient require insulin therapy within 12 week Visit 1 . Note : patient receive brief period insulin treatment ( e.g. , several day hospitalization ) longer require insulin treatment may participate Patient currently within 12 week Visit 1 take TZD agent monotherapy combination Patient currently within 12 week Visit 1 take Byetta . Patient corticosteroids Patient history malignancy ≤5 year prior sign inform consent , &gt; 5 year without documentation remission/cure Exception : Adequately treat basal cell squamous cell skin cancer situ cervical cancer . Melanoma , leukemia , lymphoma myeloproliferative disorder duration exclude Patient chemotherapy Patient receive another investigational drug last 12 week . Patients concomitant liver disease AST &gt; 3 fold upper limit normal Patients kidney disease CR &gt; 1.4 mg/dl Patients anemia ( Hb &lt; 11 gr male 10 gr female ) Patient active vascular disease ( coronary , peripheral cerebrovascular ) Patient poorly control hypertension define systolic blood pressure &gt; 160 mm Hg diastolic &gt; 95 mm Hg Proliferative retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>